Top Page
Hydration Pharmaceuticals Co. Ltd.
(Sydney:HPC)
Hydration Pharmaceuticals Co. Ltd. (HPC) vs. iShares MSCI Australia ETF (EWA)
Hydration Pharmaceuticals Co. Ltd. Business Overview & Revenue Model
Hydration Pharmaceuticals Co. Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.70M | 3.20M | 10.04M | 9.10M | 5.92M | 3.76M |
| Gross Profit | 5.43M | 1.62M | 5.39M | 4.70M | 2.58M | 1.34M |
| EBITDA | -822.10K | -3.91M | -7.46M | -10.52M | -6.08M | -3.28M |
| Net Income | -7.68M | 2.67M | -8.10M | -10.61M | -8.97M | -743.66K |
Balance Sheet | ||||||
| Total Assets | 4.20M | 5.00M | 6.69M | 10.39M | 15.31M | 4.45M |
| Cash, Cash Equivalents and Short-Term Investments | 2.74M | 3.22M | 1.84M | 4.69M | 10.67M | 1.64M |
| Total Debt | 0.00 | 0.00 | 3.89M | 3.71M | 0.00 | 0.00 |
| Total Liabilities | 1.76M | 2.25M | 7.05M | 6.41M | 2.08M | 2.42M |
| Stockholders Equity | 2.39M | 2.74M | ― | 3.98M | 13.23M | 2.00M |
Cash Flow | ||||||
| Free Cash Flow | -4.91M | -3.02M | -5.73M | -9.75M | -8.08M | -3.88M |
| Operating Cash Flow | -4.91M | -3.02M | -5.73M | -9.75M | -8.08M | -3.86M |
| Investing Cash Flow | 0.00 | 9.44M | 0.00 | 0.00 | -2.15K | 2.73M |
| Financing Cash Flow | 3.81M | -3.63M | 2.72M | 4.08M | 17.03M | 0.00 |
Hydration Pharmaceuticals Co. Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.41B | 0.36 | -61.88% | 2.34% | 16.99% | 1.69% | |
42 Neutral | ― | ― | -3.04% | 45.30% | |||
| $3.69B | 36.06 | 13.75% | 0.97% | ― | ― | ||
| $450.58M | 13.91 | 4.68% | 6.40% | ― | ― | ||
| $4.17B | 40.80 | 3.25% | 5.02% | ― | ― | ||
64 Neutral | AU$91.85M | 20.30 | 6.80% | 2.78% | 15.48% | 135.65% |
Hydration Pharmaceuticals Co. Ltd. Corporate Events
Hydration Pharmaceuticals Co. Ltd. has announced a change in the interests of a substantial holder, which is related to a share dilution event. The voting power of the substantial holder has decreased from 7.50% to 5.22%, reflecting the impact of this dilution on their stake in the company. This change could influence the company’s governance dynamics and potentially affect investor perceptions.
Hydration Pharmaceuticals Co. Ltd. has announced that its upcoming annual general meeting of shareholders will be held virtually on May 28, 2025. Shareholders are encouraged to vote by proxy and can participate in the meeting online, with the opportunity to ask questions and vote. The company emphasizes the importance of reviewing the Notice and Explanatory Memorandum for details on the resolutions to be discussed.
Hydration Pharmaceuticals Co. Ltd. has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, to be held online via Automic’s Investor Portal. The meeting will allow shareholders to participate virtually, vote on resolutions, and engage with the company’s directors. This move towards a virtual AGM reflects the company’s adaptation to digital trends, potentially increasing shareholder engagement and accessibility.
Hydration Pharmaceuticals Co. Ltd. has announced the quotation of 13,387,853 fully paid ordinary securities on the ASX, effective April 22, 2025. This move is part of a previously announced transaction, potentially impacting the company’s market presence and providing stakeholders with new investment opportunities.
Hydration Pharmaceuticals Co. Ltd. announced the completion of its Rights Issue, which offered 1 new share for every 5 existing shares at $0.01 per share. The Rights Issue, combined with a Placement, raised a total of $650,000 before costs. With 13,387,853 new shares accepted, a significant shortfall of 47,594,949 shares remains, which the company may place within three months. This capital raising effort is expected to impact the company’s financial positioning and shareholder value.
Hydration Pharmaceuticals Co. Ltd. has announced the appointment of Joseph Constable as a new director, effective April 11, 2025. Joseph Constable holds significant interests in the company, including 91,080 fully paid ordinary shares as a registered holder and additional shares through entities where he has voting and disposal control. This appointment and the disclosure of his substantial shareholding could impact the company’s governance and potentially influence strategic decisions, reflecting a consolidation of leadership and investment in the company’s future direction.
Hydration Pharmaceuticals Co. Ltd. reported a 16% increase in net sales for Q1 2025 from its US operations, achieving US$719,996 in unaudited net sales. The company has implemented significant cost reduction measures, including reducing its workforce and relocating financial duties to Australia, resulting in annual savings of US$665,000. These strategic moves, along with a focus on high-margin SKUs and new product development targeting brain and gut health, position the company to maintain its operational and financial momentum.
Hydration Pharmaceuticals Co. Ltd. has released its corporate governance statement for the financial year ending December 31, 2024, in compliance with ASX Listing Rules. The statement, available on the company’s website, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, ensuring transparency and accountability in its operations. This move reinforces the company’s commitment to maintaining high governance standards, which is crucial for its stakeholders and market reputation.
Hydration Pharmaceuticals Co. Ltd. has released its consolidated financial statements for the year ending December 31, 2024. This release provides stakeholders with insights into the company’s financial health, including profit or loss, cash flows, and changes in equity, which are crucial for assessing its operational performance and market positioning.
Hydration Pharmaceuticals Co. Ltd. has experienced changes in its substantial holdings, with Regal Funds Management Pty Limited and its associates adjusting their voting power. The changes in holdings may impact the company’s market positioning and influence within the industry, as substantial holders play a significant role in strategic decisions.
The Hydration Pharmaceuticals Company Limited has announced that Constable Group has become a substantial holder in the company, with a 16.2% voting power through its acquisition of 60,091,080 fully paid ordinary shares. This development signifies a notable shift in the company’s shareholder structure, potentially impacting its strategic direction and stakeholder dynamics.
Hydration Pharmaceuticals Co. Ltd. has announced a non-renounceable pro rata entitlement offer to raise approximately $610,000 through the issuance of new shares at $0.01 each. This capital raising effort, managed by Evolution Capital Pty Ltd., is aimed at strengthening the company’s financial position, though it is not underwritten and is considered a highly speculative investment. The offer is not extended to shareholders outside of Australia and New Zealand, reflecting the company’s current market focus.
Hydration Pharmaceuticals Co. Ltd. has issued 65,000,000 fully paid ordinary shares at $0.01 each to sophisticated and professional investors, as part of a placement announced earlier in March 2025. This move, conducted without disclosure to investors under Part 6D.2 of the Corporations Act, indicates the company’s compliance with relevant legal provisions and suggests a strategic effort to raise capital, potentially impacting its market positioning and stakeholder interests.
Hydration Pharmaceuticals Co. Ltd. announced the quotation of 65,000,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective March 26, 2025. This move is part of a previously announced transaction, potentially impacting the company’s market presence and providing stakeholders with increased liquidity and investment opportunities.
Hydration Pharmaceuticals Co. Ltd. has announced a correction to the issue date of shares under its Entitlement Offer. This update is part of a proposed non-renounceable pro rata issue of securities, which is intended to be quoted on the ASX. The correction ensures compliance with ASX listing rules and maintains transparency for stakeholders.
Hydration Pharmaceuticals Co. Ltd. announced a proposed issue of securities, including a standard pro rata issue of 61 million ordinary fully paid securities and a placement of 65 million securities. This move is likely aimed at raising capital to support the company’s operations and growth, potentially enhancing its market position and providing value to stakeholders.
Hydralyte USA has announced an amendment to the timetable for its Rights Issue, part of a broader capital raising effort. The company aims to raise a total of $1.26 million through a placement of shares and a pro rata entitlement offer. The adjustment to the Rights Issue timetable does not affect the overall capital raising plan, which remains on track, potentially impacting the company’s financial flexibility and market positioning.
Hydralyte USA has announced a pro rata, non-renounceable entitlement offer to raise approximately $610,000 by issuing new shares to eligible shareholders in Australia and New Zealand. Additionally, the company is conducting a placement to raise $650,000, with significant participation from its major shareholder, PURE Asset Management. This financial strategy aims to bolster the company’s capital without materially affecting its control structure, as the entitlement offer is not underwritten and is complemented by the placement.
Hydralyte USA has announced a strategic placement and rights issue to raise up to $1.25 million, with $650,000 already committed through the issuance of 65 million new shares. The capital raised will support the company’s US operations, including the launch of new high-margin products and the consolidation of growth trends. The appointment of Joseph Constable as a Non-Executive Director is expected to strengthen the company’s leadership. The company has also completed a transition services agreement with Prestige Consumer Healthcare, allowing it to focus solely on its US business. This financial maneuver aims to enhance operational efficiency and profitability, with significant reductions in operational expenditure anticipated.
Hydration Pharmaceuticals Co. Ltd. has announced its upcoming annual general meeting (AGM) scheduled for May 28, 2025. The company has set a deadline for director nominations by March 21, 2025, and will issue further details to shareholders in a separate notice. This announcement is part of the company’s regular governance activities and is crucial for stakeholders to participate in the decision-making process.
Hydralyte North America reported a significant financial turnaround for the year ending December 2024, driven by the strategic divestiture of its non-US assets to Prestige Consumer Healthcare Inc. This move resulted in a net profit of US$2.838 million, a stark contrast to the previous year’s loss. The proceeds from the sale were used to eliminate debt, leaving the company with a strong cash position and enabling a focused growth strategy in the US market. The company has streamlined operations to concentrate on high-margin SKUs, resulting in increased gross margins and robust sales growth, particularly through ecommerce channels. This strategic shift has positioned Hydralyte North America to capitalize on its US market presence, with early 2025 sales figures already showing significant year-on-year growth.
Hydration Pharmaceuticals Co. Ltd. reported a significant decline in revenue and an increased net loss for the fiscal year ending December 2024, primarily due to the Rite Aid bankruptcy and strategic exits from low-profit regions and products. The company completed the divestiture of its non-US assets to Prestige Consumer Healthcare Inc., retaining its US operations and using the proceeds to repay debt and restructure. This strategic shift allows the company to focus on high-margin products and leverage its intellectual property in the US market, aiming for profitability and growth through ecommerce channels.